Trials / Terminated
TerminatedNCT05237713
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Leipzig · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hematologic improvement of erythrocytes after 6 months of canakinumab treatment.
Detailed description
To study the erythroid response rate (HI-E) of canakinumab in patients with IPSS-R very low, low, or intermediate risk MDS or MDS/MPN after 6 months of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canakinumab Injection | Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years |
Timeline
- Start date
- 2022-04-26
- Primary completion
- 2024-02-29
- Completion
- 2024-02-29
- First posted
- 2022-02-14
- Last updated
- 2024-05-06
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT05237713. Inclusion in this directory is not an endorsement.